Cascade Investment Advisors Inc. Purchases 187 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Cascade Investment Advisors Inc. increased its position in shares of Gilead Sciences, Inc. (NASDAQ:GILDGet Rating) by 0.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 24,782 shares of the biopharmaceutical company’s stock after acquiring an additional 187 shares during the period. Gilead Sciences makes up about 1.1% of Cascade Investment Advisors Inc.’s holdings, making the stock its 25th biggest position. Cascade Investment Advisors Inc.’s holdings in Gilead Sciences were worth $1,799,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of GILD. FSB Premier Wealth Management Inc. bought a new stake in Gilead Sciences during the 4th quarter worth approximately $28,000. OLD Second National Bank of Aurora increased its holdings in shares of Gilead Sciences by 46.3% in the 3rd quarter. OLD Second National Bank of Aurora now owns 439 shares of the biopharmaceutical company’s stock worth $31,000 after buying an additional 139 shares during the last quarter. Capital Advisors Ltd. LLC increased its holdings in shares of Gilead Sciences by 127.6% in the 4th quarter. Capital Advisors Ltd. LLC now owns 446 shares of the biopharmaceutical company’s stock worth $32,000 after buying an additional 250 shares during the last quarter. Dark Forest Capital Management LP bought a new position in shares of Gilead Sciences in the 3rd quarter worth $34,000. Finally, Central Bank & Trust Co. bought a new position in shares of Gilead Sciences in the 4th quarter worth $36,000. 80.16% of the stock is currently owned by institutional investors and hedge funds.

In other news, EVP Brett A. Pletcher sold 3,634 shares of the firm’s stock in a transaction dated Friday, March 11th. The shares were sold at an average price of $58.24, for a total value of $211,644.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 0.16% of the company’s stock.

GILD traded down $0.11 during trading on Friday, hitting $62.37. 9,514,690 shares of the stock traded hands, compared to its average volume of 8,039,876. The firm has a market capitalization of $78.23 billion, a P/E ratio of 17.42, a price-to-earnings-growth ratio of 0.43 and a beta of 0.38. The company has a debt-to-equity ratio of 1.31, a current ratio of 1.48 and a quick ratio of 1.30. The firm has a 50-day moving average of $60.61 and a 200 day moving average of $65.27. Gilead Sciences, Inc. has a 12-month low of $57.19 and a 12-month high of $74.12.

Gilead Sciences (NASDAQ:GILDGet Rating) last announced its quarterly earnings results on Thursday, April 28th. The biopharmaceutical company reported $2.12 earnings per share for the quarter, beating the consensus estimate of $1.77 by $0.35. The business had revenue of $6.59 billion during the quarter, compared to analysts’ expectations of $6.28 billion. Gilead Sciences had a net margin of 16.43% and a return on equity of 44.98%. The firm’s revenue for the quarter was up 2.6% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.08 EPS. As a group, equities analysts predict that Gilead Sciences, Inc. will post 6.62 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Wednesday, June 29th. Shareholders of record on Wednesday, June 15th will be given a dividend of $0.73 per share. The ex-dividend date of this dividend is Tuesday, June 14th. This represents a $2.92 annualized dividend and a yield of 4.68%. Gilead Sciences’s payout ratio is currently 81.56%.

A number of brokerages have recently commented on GILD. Piper Sandler increased their price target on shares of Gilead Sciences from $72.00 to $73.00 in a report on Friday, April 29th. Morgan Stanley decreased their price target on shares of Gilead Sciences from $69.00 to $63.00 and set an “equal weight” rating on the stock in a report on Tuesday, April 12th. Truist Financial decreased their price target on shares of Gilead Sciences from $77.00 to $75.00 and set a “hold” rating on the stock in a report on Wednesday, February 2nd. Wells Fargo & Company decreased their price target on shares of Gilead Sciences from $70.00 to $63.00 and set an “equal weight” rating on the stock in a report on Tuesday, March 22nd. Finally, Oppenheimer cut their price objective on shares of Gilead Sciences from $100.00 to $90.00 in a research note on Thursday, February 3rd. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and seven have given a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and an average target price of $72.93.

About Gilead Sciences (Get Rating)

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases.

Featured Articles

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.